SurGal Clinic s.r.o.

Az itteni vizsgálatok

Miről szól a helyszín 22 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Colitis ulcerosa15 vizsgálat
• Crohn-betegség9 vizsgálat

Fázis

• 2. fázis14 vizsgálat
• 3. fázis8 vizsgálat

Állapot

• Toboroz10 vizsgálat
• Lezárult7 vizsgálat
• Fut, nem toboroz4 vizsgálat
• Még nem toboroz1 vizsgálat

Fő szponzor

• Abivax S.A.3 vizsgálat
• Takeda3 vizsgálat
• AbbVie2 vizsgálat
• Hoffmann-La Roche2 vizsgálat
• Sanofi-Aventis Recherche & Developpement2 vizsgálat
• és még 9

Futó vizsgálatok

• Toboroz

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· 2. fázis· Agomab Spain S.L.U.· Forrás

• Meghívásos bevonás

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· 2. fázis· Spyre Therapeutics, Inc.· Forrás

• Toboroz

  A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease

  2025-522001-38-00· 2. fázis· Mirador Therapeutics Inc.· Forrás

• Toboroz

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

  NCT06764615· 2. fázis· Takeda· Forrás

• Toboroz

  A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  NCT07012395· 2. fázis· Spyre Therapeutics, Inc.· Forrás

• Toboroz

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás

• Toboroz

  Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  NCT06456593· 2. fázis· Abivax S.A.· Forrás

• Fut, nem toboroz

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· 3. fázis· Hoffmann-La Roche· Forrás

• Toboroz

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· 2. fázis· AbbVie· Forrás

• Toboroz

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás

• Fut, nem toboroz

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06254950· 2. fázis· Takeda· Forrás

• Toboroz

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· 2. fázis· Takeda· Forrás

• Fut, nem toboroz

  ABTECT - Maintenance

  NCT05535946· 3. fázis· Abivax S.A.· Forrás

• Fut, nem toboroz

  A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

  NCT03398135· 3. fázis· AbbVie· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Crohn-betegség7 toboroz
• Colitis ulcerosa5 toboroz

Lezárt vizsgálatok

• Lezárult

  A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis

  NCT07222189· 2. fázis· Sanofi-Aventis Recherche & Developpement· Forrás

• Lezárult

  A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.

  NCT06637631· 2. fázis· Sanofi-Aventis Recherche & Developpement· Forrás

• Toboroz

  An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

  2023-507853-13-00· 2. fázis· Eli Lilly & Co.· Forrás

• Lezárult

  A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.

  NCT06176560· 3. fázis· Faes Farma S.A.· Forrás

• Lezárult

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· 2. fázis· Genentech Inc.· Forrás

• Lezárult

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· 3. fázis· Eli Lilly and Company· Forrás

• Lezárult

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· 3. fázis· Abivax S.A.· Forrás